Why the study?
This study was designed to investigate the hemodynamic effect of the PDE4 inhibitor rolipram in normal rat hearts both in vivo and in vitro and its underlying mechanism.
Does rolipram improve cardiac contractility in normal rat hearts?
Does rolipram improve cardiac contractility in normal rat hearts?
Rolipram exerts a positive inotropic effect in rat hearts by enhancing SERCA2a activity, suggesting PDE4 inhibition as a potential target for heart failure.
Answers are grounded in this paper and cite their sources.
Rolipram improves contractility in normal rat hearts; hypothesis-generating for PDE4 inhibition in heart failure models.
This study was designed to investigate the hemodynamic effect of rolipram, a phosphodiesterase type 4 (PDE4) inhibitor, in normal rat hearts both in vivo and in vitro and its underlying mechanism. The pressure-volume loop, isolated heart and Ca2+ transients triggered by field stimulation or caffeine were used to analyze the hemodynamic mechanism of rolipram. The results demonstrated that rolipram (3 mg/kg, ip) significantly increased the in vivo rat heart contractility by enhancing stroke work, cardiac output, stroke volume, end-systolic volume, end-diastolic volume, end-systolic pressure, heart rate, ejection fraction, peak rate of rise of left pressure (+dp/dtmax), the slopes of end-systolic pressure-volume relationship (Slope of ESPVR) or named as left-ventricular end-systolic elastance and reduced the slopes of end-diastolic pressure-volume relationship (Slope of EDPVR). Meanwhile the systolic blood pressure, diastolic blood pressure and pulse pressure were significantly enhanced by rolipram. Also, rolipram deviated normal ventricular-arterial coupling without changing the arterial elastance. Furthermore, rolipram (0.1, 1, 10 µM) also exerted positive inotropic effect in isolated rat hearts by increasing the left ventricular development pressure, and +dp/dtmax in non-paced and paced modes. Rolipram (10µM) increased the SERCA2a activity, Ca2+ content andCa2+ leak rate without changing diastolic Ca2+ level. Rolipram had significant positive inotropic effect with less effect on peripheral vascular elastance and its underlying mechanism was mediated by increasing SERCA2a activity. PDE4 inhibition by rolipram resulted in a positive inotropic effect and might serve as a target for developing agents for the treatment of heart failure in clinical settings.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: